Liabilities in USD of Propanc Biopharma, Inc. from Q2 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
Propanc Biopharma, Inc. quarterly Liabilities history and change rate from Q2 2011 to Q3 2025.
  • Propanc Biopharma, Inc. Liabilities for the quarter ending 30 Sep 2025 was $3.61M, a 13.4% decline year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Change (%)

Propanc Biopharma, Inc. Quarterly Liabilities (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $3.61M -$557K -13.4% 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $5.73M +$1.87M +48.7% 30 Jun 2025 10-Q 14 Nov 2025
Q1 2025 $4.44M +$698K +18.7% 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $4.24M +$432K +11.3% 31 Dec 2024 10-Q 14 Feb 2025
Q3 2024 $4.17M +$1M +31.6% 30 Sep 2024 10-Q 14 Nov 2024
Q2 2024 $3.85M +$674K +21.2% 30 Jun 2024 10-K 29 Sep 2025
Q1 2024 $3.74M +$652K +21.1% 31 Mar 2024 10-Q 15 May 2024
Q4 2023 $3.81M +$782K +25.9% 31 Dec 2023 10-Q 20 Feb 2024
Q3 2023 $3.17M +$308K +10.8% 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 $3.18M +$72.2K +2.33% 30 Jun 2023 10-K 30 Sep 2024
Q1 2023 $3.09M -$31.7K -1.02% 31 Mar 2023 10-Q 15 May 2023
Q4 2022 $3.02M -$16.9K -0.56% 31 Dec 2022 10-Q 10 Feb 2023
Q3 2022 $2.86M +$493K +20.8% 30 Sep 2022 10-Q 14 Nov 2022
Q2 2022 $3.11M +$24.6K +0.8% 30 Jun 2022 10-K 28 Sep 2023
Q1 2022 $3.12M +$85.2K +2.81% 31 Mar 2022 10-Q 16 May 2022
Q4 2021 $3.04M -$608K -16.7% 31 Dec 2021 10-Q 14 Feb 2022
Q3 2021 $2.37M -$944K -28.5% 30 Sep 2021 10-Q 12 Nov 2021
Q2 2021 $3.08M -$659K -17.6% 30 Jun 2021 10-K 28 Sep 2022
Q1 2021 $3.03M -$1.88M -38.3% 31 Mar 2021 10-Q 14 May 2021
Q4 2020 $3.65M -$2.09M -36.4% 31 Dec 2020 10-Q 12 Feb 2021
Q3 2020 $3.31M -$1.43M -30.1% 30 Sep 2020 10-Q 16 Nov 2020
Q2 2020 $3.74M -$663K -15.1% 30 Jun 2020 10-K 28 Sep 2021
Q1 2020 $4.91M 31 Mar 2020 10-Q 15 May 2020
Q4 2019 $5.74M 31 Dec 2019 10-Q 14 Feb 2020
Q3 2019 $4.74M 30 Sep 2019 10-Q 14 Nov 2019
Q2 2019 $4.4M 30 Jun 2019 10-K 01 Oct 2020
Q2 2012 $584K +$277K +90.4% 30 Jun 2012 10-K 15 Oct 2012
Q1 2012 $482K 31 Mar 2012 10-Q 21 May 2012
Q4 2011 $354K 31 Dec 2011 10-Q/A 07 Mar 2012
Q2 2011 $307K 30 Jun 2011 10-K 15 Oct 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.